CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Sarepta Therapeutics, Inc. - SRPT CFD

128.58
1.28%
Market Trading Hours* (UTC) Opens on Wednesday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.78
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 130.68
Open 129.91
1-Year Change -12.5%
Day's Range 127.61 - 130.19
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 20, 2024 130.68 -0.60 -0.46% 131.28 131.50 128.25
May 17, 2024 131.26 -1.38 -1.04% 132.64 132.64 129.05
May 16, 2024 132.50 1.57 1.20% 130.93 132.92 128.81
May 15, 2024 132.34 0.11 0.08% 132.23 134.43 131.68
May 14, 2024 132.61 0.25 0.19% 132.36 133.31 130.27
May 13, 2024 131.68 -0.11 -0.08% 131.79 132.43 129.27
May 10, 2024 131.77 0.66 0.50% 131.11 132.57 128.93
May 9, 2024 132.25 0.47 0.36% 131.78 133.22 129.16
May 8, 2024 132.47 -3.70 -2.72% 136.17 136.17 129.33
May 7, 2024 135.99 2.00 1.49% 133.99 145.60 131.93
May 6, 2024 134.92 3.11 2.36% 131.81 134.95 131.00
May 3, 2024 133.56 2.61 1.99% 130.95 134.33 130.40
May 2, 2024 130.43 -9.64 -6.88% 140.07 141.57 129.51
May 1, 2024 130.48 3.96 3.13% 126.52 131.42 126.52
Apr 30, 2024 125.92 -0.57 -0.45% 126.49 129.49 125.76
Apr 29, 2024 128.65 0.70 0.55% 127.95 131.63 127.26
Apr 26, 2024 128.15 1.75 1.38% 126.40 131.08 125.07
Apr 25, 2024 126.56 4.58 3.75% 121.98 130.39 121.10
Apr 24, 2024 123.61 7.22 6.20% 116.39 124.85 115.68
Apr 23, 2024 116.93 0.84 0.72% 116.09 119.79 116.09

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Sarepta Company profile

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Industry: Bio Therapeutic Drugs

215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US

News

UK CPI Preview: Will inflation return to 2% as the BoE predicts? And how will it affect GBP?

The latest round of inflation data will be released at 22 April at 7 am BST and investors are likely going to be paying close attention.

15:44, 21 May 2024

Reserve Bank of New Zealand Preview: RBNZ could become more dovish as inflation eases and growth softens

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, May 22, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

15:29, 21 May 2024

Nvidia Q1 Earnings Preview: Analysts forecast another blockbuster set of results

Nvidia (NVDA) reports its Q1 results after the closing bell on Wednesday, May 22nd. We preview what to expect from Nvidia’s earnings and analyse its stock's technicals.

14:57, 21 May 2024
CPI, consumer price index symbol.

Disinflation resumes in the US as CPI drops in April

The rate of growth in US consumer prices dropped in April leading markets to price in more chances of rate cuts from the Fed

11:24, 16 May 2024

Stock market crash: how far can the S&P 500 go?

After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.

11:46, 10 May 2024

Bank of England preview: possible rate cut in summer?

The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.

12:39, 8 May 2024

We’re partnering with Newsquawk

Filter out the noise and focus on the news that matters.

08:32, 23 April 2024

People also watch

BTC/USD

70,272.45 Price
+0.910% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,422.53 Price
-0.170% 1D Chg, %
Long position overnight fee -0.0194%
Short position overnight fee 0.0112%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.54 Price
+0.760% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Oil - Crude

78.24 Price
-1.190% 1D Chg, %
Long position overnight fee 0.0017%
Short position overnight fee -0.0237%
Overnight fee time 21:00 (UTC)
Spread 0.040

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading